Results of First General Meeting
|
Arix Bioscience PLC (ARIX)
THIS ANNOUNCEMENT AND THE INFORMATION CONTAINED IN IT ARE NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN, INTO OR FROM, FOR IMMEDIATE RELEASE Legal Entity Identifier: 213800OVT3AHQCXNIX43 RECOMMENDED ALL-SHARE ACQUISITION OF THE ASSETS OF ARIX BIOSCIENCE PLC ("Arix") BY RTW BIOTECH OPPORTUNITIES LTD ("RTW Bio") Results of First General Meeting On In connection with the Scheme, the Board is pleased to announce that at the First General Meeting held earlier today, the Resolution proposed (which was proposed as a special resolution) to, among other things, approve the Scheme, authorise the Board and the Liquidators (conditional on their appointment) to implement the Scheme and do all things necessary for the purpose of carrying the Scheme into effect, empower the Liquidators (conditional upon their appointment) to accept the Consideration Shares for distribution to eligible Shareholders and apply to delist the Shares, and, conditional upon the Scheme becoming effective, amend the Articles to give effect to the Scheme, was passed by the requisite majority of Shareholders. The full text of the Resolution is set out in the notice of the First General Meeting contained in the circular published by Arix on Number of votes cast at the General Meeting The results of the poll on the Resolution proposed at the First General Meeting held on
Votes "For" and "Against" are expressed as a percentage of the total votes received. All percentages rounded to two decimal places. *The votes "For" include those votes giving the Chairman discretion. ** "Votes Withheld" are not a vote in law and have not been counted in the calculation of the "Votes For" and "Votes Against" the Resolution or the total number of votes validly cast. A copy of the Resolution passed at the First General Meeting will be submitted to the National Storage Mechanism and will be available for inspection at: https://data.fca.org.uk/#/nsm/nationalstoragemechanism. The voting results will also shortly be available on Arix's website at https://arixbioscience.com/investor-relations. Next Steps As further detailed in the Circular, completion of the Scheme remains subject to, amongst other things, the passing of the Resolution to be proposed at the Second General Meeting. The Second General Meeting will be held at Clifford Chance LLP, Shareholders are requested to complete, sign and return the form of proxy for the Second General Meeting, or appoint a proxy through the CREST electronic proxy appointment service (as appropriate), as soon as possible and in any event by The Resolution to be considered at the Second General Meeting (which will be proposed as a special resolution) will, if passed, place the Company into members' voluntary liquidation, appoint the Liquidators and authorise the Liquidators to exercise certain powers for which the express sanction of Shareholders is required. The Resolution to be proposed at the Second General Meeting will require the approval of at least 75 per cent. of the votes cast in respect of it. Capitalised terms used but not defined in this announcement have the meanings given to them in the Circular. Enquiries:
Important information Jefferies International Limited ("Jefferies"), which is authorised and regulated by the Financial Conduct Authority in the Notice to US Shareholders in Arix This announcement is not for publication or distribution, directly or indirectly, in or into The Consideration Shares will be offered and sold for investment purposes only in RTW Bio is not registered, and does not intend to be subject to registration, as an investment company under the 1940 Act in reliance upon one or more exclusions or exemptions from registration thereunder. The Consideration Shares are subject to restrictions on transferability and resale and may not be transferred or resold except as permitted under the Securities Act, the 1940 Act and any applicable state and other securities laws, pursuant to registration or an exclusion or exemption therefrom. The transferability of the Consideration Shares will be further restricted by the terms of the AI/QP Investor Letter, and any re-offer or resale of any Consideration Shares in General If you are in any doubt about the contents of this announcement or the action you should take, you are recommended to seek your own independent financial advice immediately from your stockbroker, bank manager, solicitor or independent financial adviser duly authorised under the Financial Services and Markets Act 2000 (as amended) if you are resident in the Dissemination of a Regulatory Announcement, transmitted by EQS Group. The issuer is solely responsible for the content of this announcement. |
| ISIN: | GB00BD045071 |
| Category Code: | ROM |
| TIDM: | ARIX |
| LEI Code: | 213800OVT3AHQCXNIX43 |
| OAM Categories: | 3.1. Additional regulated information required to be disclosed under the laws of a Member State |
| Sequence No.: | 300351 |
| EQS News ID: | 1825235 |
| End of Announcement | EQS News Service |
|
|
Proactive Investors is a publisher of financial news and information. No content in this record, or published on the Proactive Investors website (the "Site"), constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. No content is tailored to any specific person's needs, objectives, or financial situation.
Proactive Investors is not registered in any category of registration under the securities legislation of any province or territory of Canada. Nothing in this record constitutes "advice" concerning investing in, buying, or selling a security within the meaning of applicable Canadian securities legislation. None of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value, or suitability of any particular security, portfolio, transaction, or investment strategy. Any decision to buy, sell, or hold a security should be made only after obtaining advice from a registrant authorised under the securities legislation of your province or territory.
This record, and any record we publish by or on behalf of our clients, should not be construed as an offer or solicitation to buy or sell any product or security. Our content is independent financial journalism, produced in a neutral, objective style with full source attribution. Where Proactive Investors has a commercial relationship with a company covered in this record, that relationship is disclosed within the article. Any such relationship is for news distribution and media services only and does not determine, influence, or shape the editorial content produced.
The Site may contain opinions from time to time regarding securities mentioned in other products, including company-related products, and those opinions may differ from those obtained through another Proactive Investors product. Opinions and commentary reflect the views of the named author at the time of writing and are subject to change without notice.
Price and other data is supplied by sources believed to be reliable. Any calculations are made using such data. Neither the data nor the calculations are guaranteed by those sources, by Proactive Investors, by the information providers, or by any other person or entity, and may not be complete or accurate.
From time to time, reference may be made in our marketing materials to previously published articles or opinions. Such references may be selective, may reference only a portion of an article, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.
FOR OUR FULL DISCLAIMER CLICK HERE